Search

Your search keyword '"Salom��o, Reinaldo"' showing total 11 results
Start Over Author "Salom��o, Reinaldo" Publication Year Range Last 3 years

Refine your results

11 results on '"Salom��o, Reinaldo"'

1. Additional file 2 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 2: Fig. S2. Representative example of the viability of MDDCs under different maturation protocols and conditions. MDDCs were isolated from PBMCs and induced to maturation according to two protocols based on IL-4 and IFN-�� as depicted in Additional file 1: Fig. S1. Maturation of MDDCs was performed starting from either freshly collected PBMCs (red bars) or PBMCs frozen in liquid nitrogen upon collection and thawed after 2 weeks. Viability was assessed by flow cytometry using a LIVE/DEAD stain. Data were normalized over the fresh-cell condition.

Published
2022
Full Text
View/download PDF

2. Additional file 11 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 11: Table S1. List of peptides used for pulsing MDDCs of each individual. Enneamers (9 mers) were designed according to their predicted immunogenicity in a given individual, as described in the main text. Peptides were then used to pulse MDDCs before their reinfusion in MDDCT recipients according to the workflow depicted in Additional file 1: Fig. S1. Note that some autologous peptides are common to more than one patient.

Published
2022
Full Text
View/download PDF

3. Additional file 7 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 7: Fig. S7. Cytokine expression in unstimulated CD4+ and CD8+ T-lymphocytes following MDDC MDDCT. Data were obtained as described in Fig. 3.

Published
2022
Full Text
View/download PDF

4. Additional file 6 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 6: Fig. S6. Cytokine expression in SEB/brefeldin-stimulated CD4+ and CD8+ T-lymphocytes following MDDC MDDCT. Data were obtained as described in Fig. 3.

Published
2022
Full Text
View/download PDF

5. Additional file 3 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Subjects
hemic and immune systems
Abstract

Additional file 3: Fig. S3. Representative example of the maturation profile of MDDCs subjected to alternative differentiation and freezing protocols. MDDCs were isolated from PBMCs and induced to maturation according to two protocols based on IL-4 and IFN-�� as depicted in Additional file 1: Fig. S1. Maturation/activation markers CD80 and HLA-DR were analyzed by flow cytometry in cells isolated from fresh PBMCs or from PBMCs thawed after freezing using FBS or a specific freezing medium (as described in the Methods section).

Published
2022
Full Text
View/download PDF

6. Additional file 5 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 5: Fig. S5. Gating strategy employed to analyze cytokine production in T-lymphocytes. Panels A, B. Cytokine production was determined in cells left unstimulated (A) or stimulated ex-vivo with the cell therapy peptides (B).

Published
2022
Full Text
View/download PDF

7. Additional file 1 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 1: Fig. S1. Schematic workflow of the protocols used for the maturation of MDDCs and MDDCT preparation. Maturation of MDDCs from monocytes was induced using either a cytokine cocktail based on IL-4 (longer protocol; Panel A) or a cytokine cocktail based on IFN-�� (shorter protocol; Panel B).

Published
2022
Full Text
View/download PDF

8. Additional file 4 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 4: Fig. S4. Gating strategy employed to analyze maturation markers of MDDCs

Published
2022
Full Text
View/download PDF

9. Additional file 9 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 9: Fig. S9. Impact of MDDCT on the level of IFN- �� in plasma. The Fig. shows the level of IFN-�� in individuals receiving the personalized dendritic-cell therapy (DCT), alone (G5, in black) or following the conditioning regimen consisting of auranofin + nicotinamide (G6, in blue). IFN-gamma was measured by ELISA testing, and data were analyzed by two-way ANOVA. The P-value reported refers to the interaction between time and the previous conditioning regimen.

Published
2022
Full Text
View/download PDF

10. Additional file 8 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 8: Fig. S8. Inter-group comparison of the immunogenicity of MDDCT. Comparison of the levels of IFN-��, IL-2, and TNF production levels by CD4+ and CD8+ T-cells in individuals receiving MDDCT only (G5) and individuals receiving MDDCT with nicotinamide and auranofin (G6). Data were analyzed by one-way ANOVA followed by Dunn��s post-test. *p

Published
2022
Full Text
View/download PDF

11. Additional file 10 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 10: Fig. S10. Impact of the time on ART on cytokine production post-MDDCT. The graph visualizes the relation between the time in days since the first MDDCT dose and the expression of immune response mediating cytokines in CD4+ (Panel A) and CD8+ (Panel B) T-cells. Patients were stratified into two categories based on the overall time of ART administration since their diagnosis (i.e. > 10 years, ���long��� and

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results